Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

Key Points

• CEO Martine Rothblatt sold 9,500 shares on March 4 at an average price of $489.91 for proceeds of $4.65 million, leaving her with 130 shares — a 98.65% reduction in her holdings.
• UTHR shares traded down to $485.06 (down $5.15) on above-average volume of 420,755, with a 12‑month range of $266.98–$537.19, a market cap of $21.26 billion and a P/E of 17.39.
• United Therapeutics reported Q results with EPS of $7.70 (beating the $6.78 estimate) but revenue of $790.2M (below the $814.8M estimate); analysts' consensus is a “Moderate Buy” (9 Buys, 3 Holds) with an average target of $539.00.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $63,688.30. This represents a 98.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

UTHR traded down $5.15 during trading on Thursday, hitting $485.06. 420,755 shares of the stock traded hands, compared to its average volume of 381,036. The business has a 50 day moving average price of $483.67 and a 200 day moving average price of $450.90. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $537.19. The company has a market cap of $21.26 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 1.79 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the business posted $6.19 EPS. The company's revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of UTHR. Rehmann Capital Advisory Group increased its stake in shares of United Therapeutics by 9.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company's stock valued at $1,767,000 after buying an additional 324 shares during the period. Tobam lifted its stake in shares of United Therapeutics by 28.9% in the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company's stock worth $4,803,000 after acquiring an additional 2,211 shares during the period. Wick Capital Partners LLC bought a new stake in United Therapeutics in the fourth quarter valued at approximately $297,000. Mishpacha Holdings Corp acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $487,000. Finally, Seven Fleet Capital Management LP bought a new position in United Therapeutics during the 4th quarter worth approximately $633,000. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. TD Cowen increased their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an "equal weight" rating in a research report on Thursday, February 26th. Bank of America reiterated a "neutral" rating on shares of United Therapeutics in a report on Wednesday, February 25th. Finally, HC Wainwright increased their price target on United Therapeutics from $525.00 to $600.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $539.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.